InvestorsHub Logo
Followers 48
Posts 12041
Boards Moderated 0
Alias Born 09/12/2017

Re: The Dark KnaDDir post# 218796

Thursday, 03/23/2023 12:33:41 PM

Thursday, March 23, 2023 12:33:41 PM

Post# of 233035
YUP! I dont see how the co and BOD is innocent or can play dumb in all of this---

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the Company has submitted the clinical, and the CMC (chemistry, manufacturing and controls) portions of its BLA to the U.S. Food and Drug Administration (FDA) for leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients. The FDA previously granted both Fast Track designation for leronlimab and rolling review for the Company’s BLA in HIV indication.

“The submission of the final two parts of the BLA is a significant milestone for the Company, and initiates its transition from a development-stage company to a commercial organization.
https://www.globenewswire.com/news-release/2020/04/27/2022519/0/en/CytoDyn-Submits-Completed-Biologics-License-Application-BLA-to-the-FDA-for-Leronlimab-as-a-Combination-Therapy-for-Highly-Treatment-Experienced-HIV-Patients.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News